Combination therapy using tnf and alfa-galactosyl ceramide
AssigneesVib Vzw, Universiteit Gent
InventorsPeter Brouckaert, Dirk Elewaut, Leander Huyghe
Life of this patent
Estimating the term…
Abstract
The invention relates to the treatment of cancer. More specifically the invention shows that the anti-cancer activity in mammals can be augmented by administering to the mammalian host a combination of a synergistically effective amount of TNF and alfa-galactosylceramide.
Claims20
A pharmaceutical composition comprising tumor necrosis factor (“TNF”) and alpha-galactosylceramide.
A method of treating cancer in a subject determined to be suffering therefrom, the method comprising:
- administering tumor necrosis factor (“TNF”) and alpha-galactosylceramide to the subject in such a manner as to reduce the subject's tumor burden or eliminate the tumor burden in the subject so as to treat the cancer.
In a method of treating a tumor in a mammal of the type comprising utilizing alpha-galactosylceramide to treat the tumor, the improvement comprising:
- parenterally administering to the mammal, in addition to the alpha-galactosylceramide, from about 50 to about 300 μg/m2 of recombinant human tumor necrosis factor (“hTNF”),
- wherein the administration of alpha-galactosylceramide and the administration of hTNF work synergistically with one another as to achieve a tumor reduction in the mammal.
Dependencies are inferred from the claim text.